SCHEMBL6016841

SCHEMBL6016841

CC(C)(C)OC(=O)C(N)C(=O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
LTA4H P09960 2/20 0.49
SYK P43405 1/20 0.49
POLB P06746 1/20 0.47
KMT2A Q03164 2/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
LAP3 P28838 1/20 0.44
SLC7A5 Q01650 1/20 0.44
PPARA Q07869 1/20 0.43
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6016194 0.88 ALDH1A1 (0.50) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL7694383 0.87 ALDH1A1 (0.59) ALDH1A1LTA4HKMT2AMAPK1L3MBTL1
SCHEMBL28628857 0.86 POLB (0.49) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL18669046 0.86 LTA4H (0.44) ALDH1A1LTA4HSYKMAPK1L3MBTL1
SCHEMBL8425022 0.84 ALDH1A1 (0.53) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL29008750 0.84 ALDH1A1 (0.53) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL8425025 0.84 ALDH1A1 (0.53) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL24689566 0.84 LTA4H (0.50) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL1731413 0.84 LTA4H (0.46) ALDH1A1LTA4HSYKPOLBKMT2A
SCHEMBL5275264 0.83 SLC1A3 (0.51) ALDH1A1LTA4HSYKPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615886-A1 [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS Warner-Lambert Company LLC (US) 2006-01-18 EP disclosed
US-20050137215-A1 [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions GUZZO PETER R (US) 2005-06-23 US disclosed
WO-2004092134-A1 [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS WARNER-LAMBERT COMPANY LLC (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137215-A1 [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions PPIC, PRAP1, PRRC2C ALDH1A1 1447/4885LTA4H 3657/4885SYK 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.